Home / Business and Economy / Druckenmiller Bets Big on Natera
Druckenmiller Bets Big on Natera
30 Aug
Summary
- Stanley Druckenmiller has a high-conviction approach to investing.
- Natera's revenue grew 37.7% year over year to $752.8 million.
- Growth is driven by Natera's oncology tests, especially Signatera.
Billionaire investor Stanley Druckenmiller, employing a high-conviction strategy, has heavily invested in Natera (NASDAQ: NTRA). His Duquesne Family Office holds 90 stocks, with 16.6% of the portfolio concentrated in Natera.
Druckenmiller first invested in Natera in the third quarter of 2022 and has increased his stake. Natera's second quarter 2026 performance showed impressive growth, with revenue climbing 37.7% year over year to $752.8 million. Over 1.04 million tests were processed, a 22.4% increase from the previous year.
The company's oncology segment is a key growth engine, processing approximately 238,000 molecular residual disease (MRD) tests in Q2 2026, a 56% jump year over year. This surge is largely attributed to Signatera, a personalized blood test that detects circulating tumor DNA.
Signatera has achieved significant regulatory milestones, including U.S. approval as a companion diagnostic for bladder cancer in May 2026. Further expansion includes Japanese regulatory approval for colorectal cancer testing in June 2026 and European Union IVDR certification for solid tumor MRD tests in July 2026.
While Druckenmiller's investment suggests confidence, potential investors should conduct their own analysis. Natera remains unprofitable, and its stock trades at approximately 17 times trailing 12-month sales, a valuation that warrants careful consideration.
